Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Heritage Mining's Contact Bay: Two Large Ni-Cu-PGE Mafic-Ultramafic Intrusives (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Context Therapeutics Inc CNTX

Healthcare
Context Therapeutics Inc. is a biopharmaceutical company focused on improving the lives of patients living with solid tumors. The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors. Its preclinical program, CTIM-76, is an anti-Claudin 6 x anti-CD3 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAb) that is intended to redirect... see more

Recent & Breaking News (NDAQ:CNTX)

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

GlobeNewswire November 9, 2023

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

GlobeNewswire October 31, 2023

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

GlobeNewswire September 27, 2023

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

GlobeNewswire August 9, 2023

Context Therapeutics to Participate in Two August 2023 Investor Conferences

GlobeNewswire August 1, 2023

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

GlobeNewswire May 10, 2023

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Accesswire April 18, 2023

Context Therapeutics to Participate in Two April 2023 Investor Conferences

GlobeNewswire April 3, 2023

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

GlobeNewswire March 22, 2023

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

GlobeNewswire March 15, 2023

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

GlobeNewswire February 6, 2023

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU(TM) (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

GlobeNewswire January 31, 2023

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

GlobeNewswire January 9, 2023

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

GlobeNewswire January 4, 2023

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

GlobeNewswire December 8, 2022

Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

TheNewsWire December 6, 2022

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

GlobeNewswire November 29, 2022

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

GlobeNewswire November 21, 2022

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

GlobeNewswire November 9, 2022

Context Therapeutics to Participate in the ThinkEquity Conference

Newsfile October 20, 2022